The value of chest and skeletal staging studies in conventional chondrosarcoma.


Journal

Skeletal radiology
ISSN: 1432-2161
Titre abrégé: Skeletal Radiol
Pays: Germany
ID NLM: 7701953

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 04 05 2020
accepted: 03 07 2020
revised: 02 07 2020
pubmed: 16 7 2020
medline: 25 6 2021
entrez: 16 7 2020
Statut: ppublish

Résumé

To determine the value of chest and skeletal staging in patients presenting with conventional chondrosarcoma (CS). Retrospective review of patients with CS diagnosed between January 2007 and December 2019. Data collected included age, sex, skeletal location and results of chest CT and whole-body bone scintigraphy (WB-BSc) obtained at initial diagnosis. The histological tumour grade based on surgical resection or needle biopsy was classified as low-grade (LGCT), high-grade (HGCT) and dedifferentiated (DD-CS). Findings of chest CT and WB-BSc were correlated with tumour grade. Four hundred twenty patients were included (234 males and 186 females with mean age 54.5 years, range 9-91 years). The major long bones were involved in 205 cases, the flat bones in 166 cases, the mobile spine in 14 cases and the small bones of the hands and feet in 35 cases. Three hundred fifty tumours were central in location, 39 peripheral and 31 on the surface of the bone. There were 151 LGCTs, 196 HGCTs and 73 DD-CSs. Of patients with LGCT, 41.7% underwent chest CT and 25.2% WB-BSc. Of patients with HGCT, 95.4% underwent chest CT and 76.5% WB-BSc. Of patients with DD-CS, 98.6% underwent chest CT and 86.3% WB-BSc. Metastases were diagnosed in 2 (3.3%) chest CT studies and 0 WB-BSc in LGCT, in 8 (4.3%) chest CT studies and 0 WB-BSc in HGCT and in 21 (30%) chest CT studies and 6 (21%) WB-BSc in DD-CS. Staging chest CT and WB-BSc is of little or no value except in DD-CS.

Identifiants

pubmed: 32666323
doi: 10.1007/s00256-020-03539-0
pii: 10.1007/s00256-020-03539-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-135

Références

Strauss SJ, Whelan JS. Current questions in bone sarcomas. Curr Opin Oncol. 2018;30(4):252–9. https://doi.org/10.1097/CCO.0000000000000456 .
doi: 10.1097/CCO.0000000000000456 pubmed: 29782347
Whelan JS, Davis LE. Osteosarcoma, chondrosarcoma, and chordoma. J Clin Oncol. 2018;36(2):188–93. https://doi.org/10.1200/JCO.2017.75.1743 Epub 2017 Dec 8.
doi: 10.1200/JCO.2017.75.1743 pubmed: 29220289
Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res BioMed Central. 2016;6(1):7.
doi: 10.1186/s13569-016-0047-1
Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79–95. https://doi.org/10.1093/annonc/mdy310 Epub 2020 Jan 7.
doi: 10.1093/annonc/mdy310 pubmed: 30285218
Miller BJ, Cram P, Lynch CF, Buckwalter JA. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. J Bone Joint Surg Am. 2013;95(13):e89. https://doi.org/10.2106/JBJS.L.01189 .
doi: 10.2106/JBJS.L.01189 pubmed: 23824394 pmcid: 3689260
Ramkumar DB, Ramkumar N, Miller BJ, Henderson ER. Risk factors for detectable metastatic disease at presentation in Ewing sarcoma - an analysis of the SEER registry. Cancer Epidemiol. 2018;57:134–9. https://doi.org/10.1016/j.canep.2018.10.013 Epub 2018 Nov 6.
doi: 10.1016/j.canep.2018.10.013 pubmed: 30412903
Xie L, Huang W, Wang H, Zheng C, Jiang J. Risk factors for lung metastasis at presentation with malignant primary osseous neoplasms: a population-based study. J Orthop Surg Res. 2020;15(1):32. https://doi.org/10.1186/s13018-020-1571-5 .
doi: 10.1186/s13018-020-1571-5 pubmed: 31996232 pmcid: 6988300
Rozeman LB, Cleton-Jansen AM, Hogendoorn PC. Pathology of primary malignant bone and cartilage tumours. Int Orthop. 2006;30(6):437–44 Epub 2006 Aug 30.
doi: 10.1007/s00264-006-0212-x
Fromm J, Klein A, Baur-Melnyk A, et al. Survival and prognostic factors in conventional central chondrosarcoma. BMC Cancer. 2018;18(1):849. https://doi.org/10.1186/s12885-018-4741-7 .
doi: 10.1186/s12885-018-4741-7 pubmed: 30143018 pmcid: 6109289
Grimer RJ, Gosheger G, Taminiau A, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer. 2007;43(14):2060–5 Epub 2007 Aug 27.
doi: 10.1016/j.ejca.2007.06.016
Miao R, Choy E, Raskin KA, et al. Prognostic factors in dedifferentiated chondrosarcoma: a retrospective analysis of a large series treated at a single institution. Sarcoma. 2019;2019:9069272. https://doi.org/10.1155/2019/9069272 eCollection 2019.
doi: 10.1155/2019/9069272 pubmed: 31915413 pmcid: 6930709
McLoughlin E, Davies AM, Iqbal A, James SL, Botchu R. The diagnostic significance of pulmonary nodules on CT thorax in chondrosarcoma of bone. Clin Radiol. 2020;75(5):395.e7–395.e16. https://doi.org/10.1016/j.crad.2019.11.017 Epub 2019 Dec 31.
doi: 10.1016/j.crad.2019.11.017
Douis H, James SL, Grimer RJ, Davies MA. Is bone scintigraphy necessary in the initial surgical staging of chondrosarcoma of bone? Skelet Radiol. 2012;41(4):429–36. https://doi.org/10.1007/s00256-011-1252-x . Epub 2011 Sep 3.
doi: 10.1007/s00256-011-1252-x
Gulia A, Puri A, Byregowda S. Staging investigations in chondrosarcoma: is evaluation for skeletal metastases justified? Analysis from an epidemiological study at a tertiary cancer care center and review of literature. South Asian J Cancer. 2016;5:3–4.
doi: 10.4103/2278-330X.179690
Caparica R, Mak MP, Rocha CH, et al. Pulmonary nodules in patients with non-pulmonary cancer: not always metastases. J Glob Oncol. 2016;2(3):138–44.
doi: 10.1200/JGO.2015.002089
Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT, Gannon FH. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics. 2003;23(5):1245–78.
doi: 10.1148/rg.235035134
Littrell LA, Wenger DE, Wold LE, et al. Radiographic, CT, and MR imaging features of dedifferentiated chondrosarcomas: a retrospective review of 174 de novo cases. Radiographics. 2004;24(5):1397–409.
doi: 10.1148/rg.245045009
Douis H, Saifuddin A. The imaging of cartilaginous bone tumours. II Chondrosarcoma. Skelet Radiol. 2013;42(5):611–26. https://doi.org/10.1007/s00256-012-1521-3 Epub 2012 Oct 4.
doi: 10.1007/s00256-012-1521-3
Deloin X, Dumaine V, Biau D, et al. Pelvic chondrosarcomas: surgical treatment options. Orthop Traumatol Surg Res. 2009;95(6):393–401. https://doi.org/10.1016/j.otsr.2009.05.004 Epub 2009 Oct 3.
doi: 10.1016/j.otsr.2009.05.004 pubmed: 19801212
Stevenson JD, Laitinen MK, Parry MC, Sumathi V, Grimer RJ, Jeys LM. The role of surgical margins in chondrosarcoma. Eur J Surg Oncol. 2018;44(9):1412–8. https://doi.org/10.1016/j.ejso.2018.05.033 Epub 2018 Jun 8.
doi: 10.1016/j.ejso.2018.05.033 pubmed: 29929901
Dierselhuis EF, Goulding KA, Stevens M, Jutte PC. Intralesional treatment versus wide resection for central low-grade chondrosarcoma of the long bones. Cochrane Database Syst Rev. 2019;3:CD010778. https://doi.org/10.1002/14651858.CD010778.pub2 .
doi: 10.1002/14651858.CD010778.pub2 pubmed: 30845364
Fromm J, Klein A, Baur-Melnyk A, et al. Survival and prognostic factors in conventional G1 chondrosarcoma. World J Surg Oncol. 2019;17(1):155. https://doi.org/10.1186/s12957-019-1695-4 .
doi: 10.1186/s12957-019-1695-4 pubmed: 31481076 pmcid: 6724259
van Praag Veroniek VM, Rueten-Budde AJ, Ho V, et al. Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surg Oncol. 2018;27(3):402–8. https://doi.org/10.1016/j.suronc.2018.05.009 Epub 2018 May 6.
doi: 10.1016/j.suronc.2018.05.009 pubmed: 30217294
Kalus S, Saifuddin A. Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review. Eur Radiol. 2019;29(10):5700–8. https://doi.org/10.1007/s00330-019-06132-9 Epub 2019 Mar 26.
doi: 10.1007/s00330-019-06132-9 pubmed: 30915559
Saifuddin A, Sharif B, Oliveira I, Kalus S, Barnett J, Pressney I. The incidence of skip metastases on whole bone MRI in high-grade bone sarcomas. Skelet Radiol. 2020;49(6):945–54. https://doi.org/10.1007/s00256-019-03369-9 Epub 2020 Jan 9.
doi: 10.1007/s00256-019-03369-9
Jurik AG, Jørgensen PH, Mortensen MM. Whole-body MRI in assessing malignant transformation in multiple hereditary exostoses and enchondromatosis: audit results and literature review. Skelet Radiol. 2020;49(1):115–24. https://doi.org/10.1007/s00256-019-03268-z Epub 2019 Jul 5.
doi: 10.1007/s00256-019-03268-z
Hanamiya M, Aoki T, Yamashita Y, Kawanami S, Korogi Y. Frequency and significance of pulmonary nodules on thin-section CT in patients with extrapulmonary malignant neoplasms. Eur J Radiol. 2012;81(1):152–7. https://doi.org/10.1016/j.ejrad.2010.08.013 Epub 2010 Sep 15.
doi: 10.1016/j.ejrad.2010.08.013 pubmed: 20828958

Auteurs

Ines Oliveira (I)

London North West Healthcare NHS Trust, London, UK. ines.oliveira1@nhs.net.

Nehal Singla (N)

The Royal National Orthopaedic Hospital, London, UK.

Anesh Chavda (A)

Chelsea and Westminster NHS Trust, Stanmore, UK.

Asif Saifuddin (A)

The Royal National Orthopaedic Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH